Study That Will Evaluate the Brazilian Population With COPD.
Prospective Multicentric Cohort Study of Severe and Very Severe COPD Patients in Brazil.
AstraZeneca
693 participants
Jan 31, 2025
OBSERVATIONAL
Conditions
Summary
Observational, prospective, multicenter cohort study with consecutive inclusion of COPD patients. Eligible patients will be those with severe and very severe COPD according to the GOLD 2024 (Global Initiative for Chronic Obstructive Lung Disease) guidelines being followed at participating hospitals. The severity of COPD is related to the exacerbation rate, which in turn is related to the progression of the disease and the occurrence of complications and death. There is no national data on this subgroup.
Eligibility
Inclusion Criteria3
- Patients of both sexes, aged 18 years or older, with confirmed COPD according to GOLD 2024: previous or current exposure and spirometry (FEV1/FVC =2 or CAT \>=10); or
- GOLD E (\>=2 moderate or 1 severe exacerbation - hospitalization); or
- GOLD 3 and 4 (FEV1 \<50%).
Exclusion Criteria3
- Advanced fibrosing interstitial lung disease (extent \>=50%); and/or
- High-risk pulmonary hypertension (on triple therapy); and/or
- Active cancer - on systemic therapy
Locations(10)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06780046